ANNXHIGH SIGNALFINANCIAL10-K

ANNX shows substantially deteriorating financial performance with meaningfully higher R&D spending and significantly increased operating cash burn as the company advances late-stage clinical programs.

The company has evolved from "clinical-stage" to advancing "two late-stage registrational programs," indicating meaningful clinical progress toward potential commercialization. However, this advancement comes with substantial cash consumption that raises questions about funding runway and the need for additional capital to reach key regulatory milestones.

Comparing 2026-03-30 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

ANNX experienced a dramatic deterioration in cash flow generation with operating cash burn substantially increasing year-over-year, driven primarily by meaningfully higher R&D expenses as the company advances its clinical programs. The balance sheet contracted meaningfully with current assets declining 23.5% and stockholders' equity falling 27.8%, while current liabilities grew 39.7%. This combination of substantially higher cash burn and shrinking asset base signals potential near-term financing needs despite the company's progress toward late-stage clinical readouts.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-57.9%
-$118.0M→-$186.4M

Operating cash flow fell 57.9% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+54.6%
$119.4M→$184.7M

R&D investment increased 54.6% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-49.6%
-$138.2M→-$206.7M

Net income declined 49.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-40.5%
-$154.1M→-$216.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+39.7%
$30.5M→$42.6M

Current liabilities surged 39.7% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
-27.8%
$293.1M→$211.6M

Equity decreased 27.8% — buybacks or losses reducing book value, monitor solvency ratios.

Current Assets
Balance Sheet
-23.5%
$316.5M→$242.2M

Current assets declined 23.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-20.7%
$350.1M→$277.6M

Total assets contracted 20.7% — asset sales, write-downs, or balance sheet optimization underway.

Total Liabilities
Balance Sheet
+15.7%
$57.0M→$65.9M

Liabilities increased 15.7% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-03
ADDED
The registrant intends to file such proxy statement with the SEC not later than 120 days after the conclusion of its fiscal year ended December 31, 2025.
You should be aware that the occurrence of any of the events discussed under the caption Risk Factors and elsewhere in this Annual Report on Form 10-K could substantially harm our business, results of operation and financial condition and cause our results to differ materially from those expressed or implied in our forward-looking statements.
Overview We are a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases that impact nearly 10 million people worldwide.
Building on more than a decade of expertise stopping acute and chronic neuroinflammation at its source, we have demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept in multiple diseases.
Our strategic priorities include advancing two late-stage registrational programs: tanruprubart, toward our first potential approval in Guillain-Barr Syndrome, or GBS, and vonaprument, toward pivotal data in geographic atrophy, or GA, as well as developing ANX1502, a novel oral small molecule for autoimmune conditions.
+7 more — sign up free →
REMOVED
Overview We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devastating inflammatory-related diseases.
We have demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept in multiple diseases, and have focused our resources on development of three priority programs: Guillain-Barr Syndrome, or GBS: We are advancing our lead candidate, ANX005, an investigational, full-length monoclonal antibody, or mAb, formulated for intravenous administration as the potential first targeted treatment for patients with GBS.
GBS is a rare antibody-mediated autoimmune disease that is the most common cause of acute neuromuscular paralysis, with no therapies in the United States approved by the FDA.
We believe maximum suppression of C1q and the classical complement cascade early in the disease process may act to rapidly prevent complement-mediated nerve damage and irreversible neurological disability.
In a prior Phase 1b placebo-controlled proof-of-concept trial, a single dose of ANX005 showed rapid and consistent improvement in muscle strength that translated into observable gains in health status, including a reduction in the need of mechanical ventilation, as well as a reduction in nerve damage and clinical function.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →